Table 1 Patient characteristics
Total number of patients (n) | 99 |
|---|---|
Combined SAA and CRP measurements (n) | 381 |
Number of visits with combined measurement per patient, median (minimum-maximum) | 3 (1–13) |
Visits while on specific medication, n (%) | Prednisone 28 (7.3%), Anakinra 59 (15.5%), Canakinumab 67 (17.6%), Tocilizumab 6 (1.6%), Colchicine 166 (43.6%), Humira 3 (0.8%), antibiotics 4 (1%) |
Male sex, n (%) | 56 (57%) |
Age (years), median (interquartile range) | 21 (11–38) |
BMI (kg/m2), mean (±SD) | 22.53 (±5.75) |
Autoinflammatory diagnoses (n) | FMF (45), CAPS (9), sJIA (5), Schnitzler syndrome (4), TRAPS (3), hidradenitis suppurativa (3), adult onset still’s disease (AOSD) (3), Behcet disease (2), PFAPA (2), MKD (2), PAPA (1), DADA2 (1) and unclassified autoinflammatory diagnosis (19) |
AA amyloidosis present, n (%) | Yes 11 (11.1%), No 88 (88.9%%) |
Ethnicity, n (%) | Caucasian 45 (45.9%), Arabic 33 (33.7%), Armenian 13 (13.1%), Asian 2 (2%), Afro-American 1 (1%), Russian 1 (1%), Georgian 1 (1%), unknown 3 (2%). |